NASHVILLE, TENNESSEE – M-LIFE™ has identified 8 drugs as prospective repurposing targets to address the cytokine storm associated with severe COVID-19 cases. As with M-Life’s™ prior list of repurposing targets directed at the virus, prospective cytokine candidates were identified via the Company’s proprietary algorithms. The prospects include: Losartan, Mepyramine, Midazolam, Pioglitazone, Raloxifene, Sarpogrelate, Suramin, and Surinabant.
Dr. John Panos, M-Life™ Director of Translational Discovery, said, “The most disturbing feature of severe COVID-19 infection is the cytokine storm which is a pro-inflammatory, immune response induced by the virus that often leads to acute respiratory distress syndrome (ARDS) and widespread multi-organ tissue damage. And while the fatal consequences of the cytokine storm are of immediate concern during infection, survivors may well experience long-lasting effects from multi organ tissue damage after recovery.”